- Conditions
- Healthy Subjects
- Interventions
- Active Comparator 1, Active Comparator 2, Control Comparator
- Dietary Supplement
- Lead sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
- Industry
- Eligibility
- 20 Years to 45 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 920
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Major Depressive Disorder, Anhedonia
- Interventions
- Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4, Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4, Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4
- Device
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Tallahassee, Florida
- Conditions
- Hallux Valgus Deformity
- Interventions
- CA-008, Placebo
- Drug
- Lead sponsor
- Concentric Analgesics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- COVID-19, Pharmacokinetics, Safety
- Interventions
- Q-Griffithsin, Placebo
- Drug
- Lead sponsor
- Sharon Hillier
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Stress Disorders, Post-Traumatic
- Interventions
- Paroxetine, Placebo
- Drug
- Lead sponsor
- Durham VA Medical Center
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Chronic Severe Plaque-type Psoriasis
- Interventions
- Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Traumatic Brain Injuries
- Interventions
- Therapeutic Benefits of Pareidolia, Active Comparator #1
- Behavioral
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Erectile Dysfunction
- Interventions
- LEVITRA (vardenafil), placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 65
- States / cities
- Fairhope, Alabama • Homewood, Alabama • Huntsville, Alabama + 61 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- RO7795081, Semaglutide, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more
- Conditions
- Urinary Tract Infection, Recurrent
- Interventions
- phage therapy, control
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 20
- States / cities
- Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
- Conditions
- Opioid Use Disorder
- Interventions
- Naltrexone implant, 14.4 grams, Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg
- Drug
- Lead sponsor
- Akyso Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Millcreek, Utah
- Conditions
- Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Physical Activity, Physical Activity Behavior, Cancer (With or Without Metastasis), Cancer - Chronic Lymphocytic Leukemia, Cancer - Ovarian
- Interventions
- Virtually Supervised Exercise Sessions, Asynchronous Group
- Behavioral
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System
- Interventions
- carmustine, radiation therapy, O6-Benzylguanine
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 163
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Fairfield, California + 105 more
- Conditions
- Tobacco Dependence
- Interventions
- CEASE, CEASE + BIO
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 865 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Obsessive-Compulsive Disorder in Children, Anxiety Disorder of Childhood, Social Anxiety Disorder of Childhood, Obsessive-Compulsive Disorder in Adolescence, Generalized Anxiety Disorder, Separation Anxiety, Panic Disorder, Panic Disorder With Agoraphobia, Panic Attacks
- Interventions
- Family Based, Internet-Based Cognitive Behavioral Therapy, Bibliotherapy, low therapist contact SPACE, Relaxation and Mentorship
- Behavioral · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 7 Years to 13 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatic Impairment, Healthy
- Interventions
- Obicetrapib
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Saint Paul, Minnesota • San Antonio, Texas
- Conditions
- Healthy Participants
- Interventions
- Staccato Alprazolam, Midazolam, Diazepam
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 20 Years to 55 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Sexual Wellness, Women Health
- Interventions
- Shatavari (Asparagus racemosus) Root Extract, Placebo Capsule
- Dietary Supplement · Other
- Lead sponsor
- SF Research Institute, Inc.
- Network
- Eligibility
- 20 Years to 50 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Autistic Disorder
- Interventions
- citalopram hydrobromide, placebo
- Drug · Other
- Lead sponsor
- Boston University
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New Haven, Connecticut • Lebanon, New Hampshire + 3 more
- Conditions
- Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
- Interventions
- E7050, Cetuximab
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 4 more
- Conditions
- Type 2 Diabetes, Cardiovascular Disease
- Interventions
- Sitagliptin, Glimepiride, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 22 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hyperlipidemia
- Interventions
- Placebo, MBX-8025, Atorvastatin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more
- Conditions
- Chronic Insomnia
- Interventions
- Experimental: Behavioral approach 1, Comparator: Behavioral approach 2
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania